| Item Type | Name |
|
Concept
|
Persistent Fetal Circulation Syndrome
|
|
Concept
|
Substance Withdrawal Syndrome
|
|
Concept
|
Premenstrual Syndrome
|
|
Concept
|
Neonatal Abstinence Syndrome
|
|
Academic Article
|
Low plasma gamma-aminobutyric acid levels during the late luteal phase of women with premenstrual dysphoric disorder.
|
|
Academic Article
|
Medical management of premenstrual dysphoric disorder.
|
|
Academic Article
|
Premenstrual disorders: bridging research and clinical reality.
|
|
Academic Article
|
Review: progesterone or progesterone lead to a marginal reduction in premenstrual syndrome symptoms.
|
|
Academic Article
|
Evidence-Based Treatments for Premenstrual Disorders.
|
|
Academic Article
|
Sertraline in the treatment of premenstrual dysphoric disorder.
|
|
Academic Article
|
Antidepressants in the treatment of premenstrual dysphoric disorder.
|
|
Academic Article
|
The association between premenstrual dysphoric disorder and other mood disorders.
|
|
Academic Article
|
Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs.
|
|
Academic Article
|
Differences in symptom scores and health outcomes in premenstrual syndrome.
|
|
Academic Article
|
CDC Grand Rounds: Public Health Strategies to Prevent Neonatal Abstinence Syndrome.
|
|
Academic Article
|
Health and economic impact of the premenstrual syndrome.
|
|
Academic Article
|
Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder.
|
|
Academic Article
|
The psychopharmacological treatment of nonmajor mood disorders.
|
|
Academic Article
|
Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase.
|
|
Academic Article
|
Adrenergic receptors in premenstrual dysphoric disorder: I. Platelet alpha 2 receptors: Gi protein coupling, phase of menstrual cycle, and prediction of luteal phase symptom severity.
|
|
Academic Article
|
Symptom-onset treatment for women with premenstrual dysphoric disorder.
|
|
Academic Article
|
ISPMD consensus on the management of premenstrual disorders.
|
|
Academic Article
|
Premenstrual disorders.
|
|
Academic Article
|
Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation.
|
|
Academic Article
|
Addressing concerns about the inclusion of premenstrual dysphoric disorder in DSM-5.
|
|
Academic Article
|
Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial.
|
|
Academic Article
|
Paroxetine treatment of mood disorders in women: premenstrual dysphoric disorder and hot flashes.
|
|
Academic Article
|
Premenstrual syndrome.
|
|
Academic Article
|
Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo.
|
|
Academic Article
|
Venlafaxine in the treatment of premenstrual dysphoric disorder.
|
|
Academic Article
|
Premenstrual dysphoric disorder: evidence for a new category for DSM-5.
|
|
Academic Article
|
Antidepressant use in pregnant and postpartum women.
|
|
Academic Article
|
Evaluating the criteria used for identification of PMS.
|
|
Academic Article
|
Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder?
|
|
Academic Article
|
Development and validation of the Premenstrual Symptoms Impact Survey (PMSIS): a disease-specific quality of life assessment tool.
|
|
Academic Article
|
Premenstrual exacerbation of depression: one process or two?
|
|
Academic Article
|
A literature review of psychotic symptoms associated with the premenstruum.
|
|
Academic Article
|
Adrenergic receptors in premenstrual dysphoric disorder. II. Neutrophil beta2-adrenergic receptors: Gs protein coupling, phase of menstrual cycle and prediction of luteal phase symptom severity.
|
|
Academic Article
|
A pilot study to compare fluoxetine, calcium, and placebo in the treatment of premenstrual syndrome.
|
|
Academic Article
|
Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group.
|
|
Academic Article
|
Pretreatment pattern of symptom expression in premenstrual dysphoric disorder.
|
|
Academic Article
|
Risk factors for premenstrual dysphoric disorder in a community sample of young women: the role of traumatic events and posttraumatic stress disorder.
|
|
Academic Article
|
Management strategies for PMS/PMDD.
|
|
Academic Article
|
Paroxetine as a treatment for premenstrual dysphoric disorder.
|
|
Academic Article
|
Special issues related to the treatment of depression in women.
|
|
Academic Article
|
Recognition of depression in obstetric/gynecology practices.
|
|
Academic Article
|
Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder.
|
|
Academic Article
|
Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies.
|
|
Academic Article
|
Using the daily record of severity of problems as a screening instrument for premenstrual syndrome.
|
|
Academic Article
|
Anxiety symptoms and anxiety disorders: how are they related to premenstrual disorders?
|
|
Academic Article
|
Substance use disorders in pregnancy: clinical,?ethical, and research imperatives of?the?opioid epidemic: a report of a joint workshop of the Society for Maternal-Fetal Medicine, American College of Obstetricians and Gynecologists, and American Society of Addiction Medicine.
|
|
Academic Article
|
The Influence of Cyclic Hormonal Contraception on Expression of Premenstrual Syndrome.
|
|
Academic Article
|
Review of fluoxetine and its clinical applications in premenstrual dysphoric disorder.
|